Real-world evidence from a single UK cancer center for atezolizumab in second-line setting in advanced urothelial cancer: Moving beyond clinical trials.
SA Hussain, M Qureshi, B Tahir, A Rehan, JWF Catto - 2022 - ascopubs.org
461 Background: Atezolizumab is approved for use in advanced urothelial cancer in second
line setting after platinum based chemotherapy. We conducted a retrospective study to …
line setting after platinum based chemotherapy. We conducted a retrospective study to …
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Background Atezolizumab can induce sustained responses in metastatic urothelial
carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab …
carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab …
Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice.
AIMS OF THE STUDY Atezolizumab is an approved therapy for urothelial carcinoma based
on results from the IMvigor 210 and IMvigor211 phase II and III trials. The global SAUL study …
on results from the IMvigor 210 and IMvigor211 phase II and III trials. The global SAUL study …
Re: Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma who have Progressed Following Treatment with Platinum-based …
BH Bochner - European Urology, 2016 - europepmc.org
This is a comment on" Atezolizumab in patients with locally advanced and metastatic
urothelial carcinoma who have progressed following treatment with platinum-based …
urothelial carcinoma who have progressed following treatment with platinum-based …
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
AV Balar, MD Galsky, JE Rosenberg, T Powles… - The Lancet, 2017 - thelancet.com
Background First-line chemotherapy for patients with cisplatin-ineligible locally advanced or
metastatic urothelial carcinoma is associated with short response duration, poor survival …
metastatic urothelial carcinoma is associated with short response duration, poor survival …
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall …
E Grande, JÁ Arranz, M De Santis, A Bamias… - The Lancet …, 2024 - thelancet.com
Background IMvigor130 demonstrated statistically significant investigator-assessed
progression-free survival benefit with first-line atezolizumab plus platinum-based …
progression-free survival benefit with first-line atezolizumab plus platinum-based …
[HTML][HTML] Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial …
Background Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved
for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a …
for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a …
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: clinical experience from an expanded access study in the United States
SK Pal, J Hoffman-Censits, H Zheng, C Kaiser… - European Urology, 2018 - Elsevier
Background Atezolizumab (anti–programmed death-ligand 1) was approved in the USA,
Europe, and elsewhere for treatment-naive and platinum-treated locally …
Europe, and elsewhere for treatment-naive and platinum-treated locally …
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: results of real-life experiences
D Tural, ÖF Ölmez, AT Sümbül, M Artaç, N Özhan… - European urology …, 2021 - Elsevier
Background Atezolizumab (ATZ) has demonstrated antitumor activity and manageable
safety in previous studies in patients with locally advanced or metastatic platinum-resistant …
safety in previous studies in patients with locally advanced or metastatic platinum-resistant …
[HTML][HTML] Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
Background Conventional criteria for tumor progression may not fully reflect the clinical
benefit of immunotherapy or appropriately guide treatment decisions. The phase II …
benefit of immunotherapy or appropriately guide treatment decisions. The phase II …